Agilent Technologies, Inc. (A) Fundamental Analysis: Bull vs. Bear Case

A

Agilent Technologies, Inc.

Fundamental data last updated:June 10, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/26/2026

Business Summary

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

VALUATION

P/E

27.51 Market Cap ($M USD)

$38.84B

Forward P/E

15.59 PEG

0.20 PRICE TO SALES

5.37 PRICE TO BOOK

5.46 EV / EBITDA

21.70 5-Year Average P/E

Free Cash Flow Yield

3.23%

DCF Value

$79.21

Graham Number

$53.19

Price to FCF

30.93 EV to FCF

32.16 Earnings Yield

3.64%

FCF Yield

3.23%

DIVIDEND

Yield

0.55%

Annual Payout

$0.75

Payout Ratio

20.16%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$5.00

Next Year EPS Growth Estimate

$8.82

Next Year Revenue Growth Estimate

$936.80B

Return on Equity (ROE)

20.84%

FREE CASH FLOW

Operating Margin

21.50%

Debt-to-Equity

0.50 Piotroski F-Score

9 Altman Z-Score

5.24 Return on Invested Capital (ROIC)

14.40%

Current Ratio

2.10 Quick Ratio

1.62 Net Debt to EBITDA

0.83 Interest Coverage

14.81 Gross Profit margin

53.00%

FCF PER SHARE

$4.44

REVENUE PER SHARE

$25.55

Gainseekers Quantitative Analysis

Summary

Agilent Technologies, Inc. appears to be mispriced relative to its intrinsic value. The stock traded above its DCF Value and Graham Number, suggesting a potential overvaluation. However, the Forward P/E of 13.43 and an impressive Altman Z-score of 4.65 indicate financial stability and growth potential. The Earnings Yield of 3.94% suggests moderate returns, but the market may be underestimating its future earnings capacity. Overall, the financial health is robust, yet the valuation may not offer a deep value opportunity at this snapshot.

AI Exposure / Tech Reliance

Operating in the Medical - Diagnostics & Research industry, Agilent is well-positioned to leverage AI and tech advancements. Its focus on diagnostics aligns with the increasing demand for precision medicine and data-driven healthcare solutions. This positioning could enhance its resilience and adaptability in a rapidly evolving tech landscape.

The Bull Case

For the discerning GARP investor, Agilent offers compelling strengths. With a solid ROIC of 13.76% and a Piotroski F-Score of 6, the company demonstrates efficient capital allocation and financial health. Its operating margin of 20.61% and a manageable Debt/Equity ratio of 0.50 highlight strong pricing power and operational efficiency. These metrics suggest that Agilent can generate sustainable cash flows and deliver consistent returns.

The Bear Case

Despite its strengths, Agilent faces structural risks. The Price/Book ratio of 4.74 and Price/Sales ratio of 4.62 indicate a premium valuation that may not be justified by its cash flow metrics. The EV to FCF ratio of 34.51 and a low FCF Yield of 3.04% suggest that cash generation is not keeping pace with its market valuation. Additionally, trading near its 52-week high, the stock may be technically overextended, posing a risk for value investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$161.44

Institutional Ownership %

1-Year Beta

1.22 Insider Buying % (6 Mo)

Distance to 52-Week High

16.60%

Distance to 52-Week Low

21.17%

EARNINGS SURPRISE %

5.67%

50-DAY SMA

$115.38

200-DAY SMA

$129.52

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.